Literature DB >> 21903448

Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma.

Bo-Lei Cai1, Xiao-Fang Xu, Shan-Min Fu, Liang-Liang Shen, Jing Zhang, Su-Min Guan, Jun-Zheng Wu.   

Abstract

Multidrug resistance-related protein 1 (MRP1 or ABCC1), a membrane-bound energy-dependent efflux transporter, is overexpressed in several kinds of multidrug-resistant cell lines and related to multidrug-resistance (MDR) of various cancers. In this study, we investigated whether MRP1 was involved in the chemoresistance of mucoepidermoid carcinoma (MEC). We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol. However, no significant quantitative difference of MRP1 mRNA and protein expression was found between MC3/5FU cells and its parental cell line (MC3) as determined by RT-PCR and Western blot. Interestingly, MRP1 was translocated from the cytoplasmic membrane of the MC3 cells to the nuclei of MC3/5FU cells as revealed by indirect immunofluorescence staining. Furthermore, MRP1 down-regulation mainly decreased the nuclear expression of MRP1 rather than the cytoplasmic membrane expression. Our results suggested that MRP1 was involved in the chemoresistance of MEC and MRP1 may confer drug-resistance by a mechanism associated with its nuclear translocation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903448     DOI: 10.1016/j.oraloncology.2011.08.005

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  7 in total

1.  Multidrug Resistance-associated Protein-1 (MRP-1)-dependent Glutathione Disulfide (GSSG) Efflux as a Critical Survival Factor for Oxidant-enriched Tumorigenic Endothelial Cells.

Authors:  Gayle M Gordillo; Ayan Biswas; Savita Khanna; James M Spieldenner; Xueliang Pan; Chandan K Sen
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

Review 2.  Salivary gland cancer stem cells.

Authors:  April Adams; Kristy Warner; Jacques E Nör
Journal:  Oral Oncol       Date:  2013-06-28       Impact factor: 5.337

3.  DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.

Authors:  Jun Fang; Zhimin Ye; Feiying Gu; Maohui Yan; Qingren Lin; Juan Lin; Zhun Wang; Yaping Xu; Yuezhen Wang
Journal:  Oncol Lett       Date:  2018-05-29       Impact factor: 2.967

4.  Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer.

Authors:  Yusuke Takashima; Shuhei Komatsu; Takuma Ohashi; Jun Kiuchi; Hajime Kamiya; Hiroki Shimizu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Takeshi Kubota; Kazuma Okamoto; Hitoshi Fujiwara; Hitoshi Tsuda; Eigo Otsuji
Journal:  Cancer Sci       Date:  2022-04-01       Impact factor: 6.518

5.  Nuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman's rank correlation analysis.

Authors:  Bolei Cai; Ye Miao; Yuan Liu; Xiaofang Xu; Sumin Guan; Junzheng Wu; Yanpu Liu
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.

Authors:  Angelika Długosz-Pokorska; Marlena Pięta; Tomasz Janecki; Anna Janecka
Journal:  Mol Biol Rep       Date:  2019-11-18       Impact factor: 2.316

7.  Nuclear Multidrug Resistance-Related Protein 1 Is Highly Associated with Better Prognosis of Human Mucoepidermoid Carcinoma through the Suppression of Cell Proliferation, Migration and Invasion.

Authors:  Bo-Lei Cai; Yan Li; Liang-Liang Shen; Jin-Long Zhao; Yuan Liu; Jun-Zheng Wu; Yan-Pu Liu; Bo Yu
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.